Aptevo Therapeutics Inc (APVO) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access APVO Annual Balance Sheets →
Reviewing balance sheet figures over time helps illustrate how Aptevo Therapeutics Inc manages its resources, obligations, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent9.80
Restricted Cash and Cash Equivalents, Current8.20
Cash & Short-term Investments17.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.54
Total Current Assets10.80
Equipment/Property/Plant Net0.24
Tax Assets, Noncurrent0.00
Other Assets, Noncurrent3.49
Total Assets14.52
Liabilities
Accounts Payable, Current AC1.16
Accrued Liabilities And Other Liabilities1.19
Other Liabilities, Current2.84
Total Current Liabilities5.19
Total Long-term Debt0.00
Deferred Tax Liabilities, Net, Noncurrent LI0.00
Other liabilities, Noncurrent3.29
Sales Rebates And Discounts Payable0.89
Total Liabilities8.48
Stockholders' Equity
Common Stock Value0.11
Additional Paid In Capital Common Stock294.19
Retained Earnings / Accumulated Deficit-288.26
Other Equity0.00
Common Stockholder's Equity6.04
Total Stockholder's Equity6.04
Liabilities & Stockholder's Equity14.52
4 historic quarters locked

Sign in to unlock the full Aptevo Therapeutics Inc balance sheet history.

About Aptevo Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-350559

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.